进展

订阅

MedSci主页 / 所有栏目 / 进展

Environ Toxicol Pharmacol：百草枯可调节小鼠骨髓的氧化应激

2018-01-16 MedSci MedSci原创

关注

目前的研究主要集中在百草枯与红细胞系统在小鼠骨髓和脾脏中的相互作用。选取C57B1/6小鼠腹腔注射（10mg/kg）百草枯，可在7,14,21天时间观察到骨髓（BM）中活性氧的水平变化，但在脾脏红细胞中无变化。在百草枯处理的小鼠中观察到BM和脾红系细胞中CD147表达的明显升高。百草枯处理也能调节类红细胞中CD47的表达，其表达水平在骨髓处理第14,21和28天以及脾脏第14和21天明显升高。BM

目前的研究主要集中在百草枯与红细胞系统在小鼠骨髓和脾脏中的相互作用。

选取C57B1/6小鼠腹腔注射（10mg/kg）百草枯，可在7,14,21天时间观察到骨髓（BM）中活性氧的水平变化，但在脾脏红细胞中无变化。在百草枯处理的小鼠中观察到BM和脾红系细胞中CD147表达的明显升高。百草枯处理也能调节类红细胞中CD47的表达，其表达水平在骨髓处理第14,21和28天以及脾脏第14和21天明显升高。BM红系细胞线粒体潜能和抗氧化基因SOD1，SOD2，GPX1和FOXO3的表达水平明显降低，而脾脏则出现逆转。

总之，这项研究表明，百草枯处理可调节C57Bl/6小鼠红细胞系统中ROS的产生，线粒体膜电位和氧化应激标记物基因表达。

原始出处：

Bhardwaj N, Singh A. Paraquat treatment modulates integrin associated protein (CD47) and basigin (CD147) expression and mitochondrial potential on erythroid cells in mice. Environ Toxicol Pharmacol. 2017 Dec 23;58:37-44. doi: 10.1016/j.etap.2017.12.007.

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1908393, encodeId=23d01908393cb, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Wed Mar 21 14:34:00 CST 2018, time=2018-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788291, encodeId=3b5c1e882916b, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Tue Oct 02 16:34:00 CST 2018, time=2018-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996127, encodeId=d8c5199612eb8, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon Sep 24 12:34:00 CST 2018, time=2018-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787425, encodeId=7a471e8742544, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Jun 24 21:34:00 CST 2018, time=2018-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399116, encodeId=f65d1399116b2, content=<a href='/topic/show?id=1812e18986d' target=_blank style='color:#2F92EE;'>#百草枯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71898, encryptionId=1812e18986d, topicName=百草枯)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19562191272, createdName=xxxx1050, createdTime=Thu Jan 18 01:34:00 CST 2018, time=2018-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445200, encodeId=da2014452000d, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Thu Jan 18 01:34:00 CST 2018, time=2018-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524254, encodeId=69011524254db, content=<a href='/topic/show?id=053710045ad' target=_blank style='color:#2F92EE;'>#iron#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10045, encryptionId=053710045ad, topicName=iron)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f1b11597510, createdName=july_979, createdTime=Thu Jan 18 01:34:00 CST 2018, time=2018-01-18, status=1, ipAttribution=)]
    2018-03-21 chentianping

    #pharma#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1908393, encodeId=23d01908393cb, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Wed Mar 21 14:34:00 CST 2018, time=2018-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788291, encodeId=3b5c1e882916b, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Tue Oct 02 16:34:00 CST 2018, time=2018-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996127, encodeId=d8c5199612eb8, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon Sep 24 12:34:00 CST 2018, time=2018-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787425, encodeId=7a471e8742544, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Jun 24 21:34:00 CST 2018, time=2018-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399116, encodeId=f65d1399116b2, content=<a href='/topic/show?id=1812e18986d' target=_blank style='color:#2F92EE;'>#百草枯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71898, encryptionId=1812e18986d, topicName=百草枯)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19562191272, createdName=xxxx1050, createdTime=Thu Jan 18 01:34:00 CST 2018, time=2018-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445200, encodeId=da2014452000d, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Thu Jan 18 01:34:00 CST 2018, time=2018-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524254, encodeId=69011524254db, content=<a href='/topic/show?id=053710045ad' target=_blank style='color:#2F92EE;'>#iron#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10045, encryptionId=053710045ad, topicName=iron)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f1b11597510, createdName=july_979, createdTime=Thu Jan 18 01:34:00 CST 2018, time=2018-01-18, status=1, ipAttribution=)]
    2018-10-02 dingxiaobo

    #Pharmacol#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1908393, encodeId=23d01908393cb, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Wed Mar 21 14:34:00 CST 2018, time=2018-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788291, encodeId=3b5c1e882916b, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Tue Oct 02 16:34:00 CST 2018, time=2018-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996127, encodeId=d8c5199612eb8, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon Sep 24 12:34:00 CST 2018, time=2018-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787425, encodeId=7a471e8742544, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Jun 24 21:34:00 CST 2018, time=2018-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399116, encodeId=f65d1399116b2, content=<a href='/topic/show?id=1812e18986d' target=_blank style='color:#2F92EE;'>#百草枯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71898, encryptionId=1812e18986d, topicName=百草枯)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19562191272, createdName=xxxx1050, createdTime=Thu Jan 18 01:34:00 CST 2018, time=2018-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445200, encodeId=da2014452000d, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Thu Jan 18 01:34:00 CST 2018, time=2018-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524254, encodeId=69011524254db, content=<a href='/topic/show?id=053710045ad' target=_blank style='color:#2F92EE;'>#iron#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10045, encryptionId=053710045ad, topicName=iron)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f1b11597510, createdName=july_979, createdTime=Thu Jan 18 01:34:00 CST 2018, time=2018-01-18, status=1, ipAttribution=)]
    2018-09-24 yb6560

    #MAC#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1908393, encodeId=23d01908393cb, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Wed Mar 21 14:34:00 CST 2018, time=2018-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788291, encodeId=3b5c1e882916b, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Tue Oct 02 16:34:00 CST 2018, time=2018-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996127, encodeId=d8c5199612eb8, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon Sep 24 12:34:00 CST 2018, time=2018-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787425, encodeId=7a471e8742544, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Jun 24 21:34:00 CST 2018, time=2018-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399116, encodeId=f65d1399116b2, content=<a href='/topic/show?id=1812e18986d' target=_blank style='color:#2F92EE;'>#百草枯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71898, encryptionId=1812e18986d, topicName=百草枯)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19562191272, createdName=xxxx1050, createdTime=Thu Jan 18 01:34:00 CST 2018, time=2018-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445200, encodeId=da2014452000d, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Thu Jan 18 01:34:00 CST 2018, time=2018-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524254, encodeId=69011524254db, content=<a href='/topic/show?id=053710045ad' target=_blank style='color:#2F92EE;'>#iron#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10045, encryptionId=053710045ad, topicName=iron)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f1b11597510, createdName=july_979, createdTime=Thu Jan 18 01:34:00 CST 2018, time=2018-01-18, status=1, ipAttribution=)]
    2018-06-24 jj000001

    #Pharm#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1908393, encodeId=23d01908393cb, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Wed Mar 21 14:34:00 CST 2018, time=2018-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788291, encodeId=3b5c1e882916b, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Tue Oct 02 16:34:00 CST 2018, time=2018-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996127, encodeId=d8c5199612eb8, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon Sep 24 12:34:00 CST 2018, time=2018-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787425, encodeId=7a471e8742544, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Jun 24 21:34:00 CST 2018, time=2018-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399116, encodeId=f65d1399116b2, content=<a href='/topic/show?id=1812e18986d' target=_blank style='color:#2F92EE;'>#百草枯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71898, encryptionId=1812e18986d, topicName=百草枯)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19562191272, createdName=xxxx1050, createdTime=Thu Jan 18 01:34:00 CST 2018, time=2018-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445200, encodeId=da2014452000d, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Thu Jan 18 01:34:00 CST 2018, time=2018-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524254, encodeId=69011524254db, content=<a href='/topic/show?id=053710045ad' target=_blank style='color:#2F92EE;'>#iron#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10045, encryptionId=053710045ad, topicName=iron)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f1b11597510, createdName=july_979, createdTime=Thu Jan 18 01:34:00 CST 2018, time=2018-01-18, status=1, ipAttribution=)]
    2018-01-18 xxxx1050

    #百草枯#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1908393, encodeId=23d01908393cb, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Wed Mar 21 14:34:00 CST 2018, time=2018-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788291, encodeId=3b5c1e882916b, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Tue Oct 02 16:34:00 CST 2018, time=2018-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996127, encodeId=d8c5199612eb8, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon Sep 24 12:34:00 CST 2018, time=2018-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787425, encodeId=7a471e8742544, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Jun 24 21:34:00 CST 2018, time=2018-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399116, encodeId=f65d1399116b2, content=<a href='/topic/show?id=1812e18986d' target=_blank style='color:#2F92EE;'>#百草枯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71898, encryptionId=1812e18986d, topicName=百草枯)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19562191272, createdName=xxxx1050, createdTime=Thu Jan 18 01:34:00 CST 2018, time=2018-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445200, encodeId=da2014452000d, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Thu Jan 18 01:34:00 CST 2018, time=2018-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524254, encodeId=69011524254db, content=<a href='/topic/show?id=053710045ad' target=_blank style='color:#2F92EE;'>#iron#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10045, encryptionId=053710045ad, topicName=iron)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f1b11597510, createdName=july_979, createdTime=Thu Jan 18 01:34:00 CST 2018, time=2018-01-18, status=1, ipAttribution=)]
    2018-01-18 ms1260584454294838

    #应激#

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1908393, encodeId=23d01908393cb, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Wed Mar 21 14:34:00 CST 2018, time=2018-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788291, encodeId=3b5c1e882916b, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Tue Oct 02 16:34:00 CST 2018, time=2018-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996127, encodeId=d8c5199612eb8, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon Sep 24 12:34:00 CST 2018, time=2018-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787425, encodeId=7a471e8742544, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Jun 24 21:34:00 CST 2018, time=2018-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399116, encodeId=f65d1399116b2, content=<a href='/topic/show?id=1812e18986d' target=_blank style='color:#2F92EE;'>#百草枯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71898, encryptionId=1812e18986d, topicName=百草枯)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19562191272, createdName=xxxx1050, createdTime=Thu Jan 18 01:34:00 CST 2018, time=2018-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445200, encodeId=da2014452000d, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Thu Jan 18 01:34:00 CST 2018, time=2018-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524254, encodeId=69011524254db, content=<a href='/topic/show?id=053710045ad' target=_blank style='color:#2F92EE;'>#iron#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10045, encryptionId=053710045ad, topicName=iron)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f1b11597510, createdName=july_979, createdTime=Thu Jan 18 01:34:00 CST 2018, time=2018-01-18, status=1, ipAttribution=)]
    2018-01-18 july_979

    #iron#

    0